Tag: RASON inhibitor drugs

Browse exclusive Tags!

Revolution Medicines Acquires EQRx, Adding $1B in Net Cash for RAS Cancer Drug Development, United States

Revolution Medicines acquires EQRx to strengthen oncology efforts. This all-stock deal provides over $1 billion in net cash for innovative drug development.

Popular

Subscribe

spot_imgspot_img